Insys Therapeutics (INSY) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
INSYS Therapeutics (INSY) PT Lifted to $76 at Piper Jaffray
March 4, 2015 10:56 AM ESTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on INSYS Therapeutics (NASDAQ: INSY) price target of $76.00 (from $64.00) following strong Q4 results for Subsys.
Amsellem commented, "Insys reported adjusted diluted EPS of $0.53 on revenues of $67M, ahead of Street estimates of $0.44... More
